Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Genmab A/S - American Depositary Shares (NQ:GMAB)

28.89 -0.27 (-0.94%)

Streaming Delayed Price Updated: 1:58 PM EST, Feb 19, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	1,257,798
Open	28.29
Bid (Size)	28.88 (200)
Ask (Size)	28.89 (400)
Prev. Close	29.16
Today's Range	28.06 - 28.95
52wk Range	17.23 - 35.43
Shares Outstanding	N/A
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Genmab A/S (NASDAQ:GMAB): A GARP Case Study in Affordable Biotech Growth ↗

February 06, 2026

Via Chartmill

GENMAB A/S (NASDAQ:GMAB) Stands Out as a Peter Lynch-Style GARP Investment ↗

January 29, 2026

Via Chartmill

Performance

YTD	-9.2%	-9.2%
1 Month	-7.8%	-7.8%
3 Month	-5.5%	-5.5%
6 Month	+20.1%	+20.1%
1 Year	+32.7%	+32.7%

More News

GENMAB A/S -SP ADR (NASDAQ:GMAB) Combines Strong Growth with Bullish Technical Formation ↗

January 26, 2026

Via Chartmill

GENMAB A/S (NASDAQ:GMAB) Presents a Compelling Blend of Strong Fundamentals and Bullish Technicals ↗

January 24, 2026

Via Chartmill

My Top 4 Stocks to Buy in Early 2026 ↗

January 22, 2026

Via The Motley Fool

Genmab Reports Mixed Results From Late-Stage Trial Of Lymphoma Drug ↗

January 16, 2026

Via Stocktwits

GENMAB A/S -SP ADR (NASDAQ:GMAB) Passes Peter Lynch's GARP Investment Screen ↗

December 31, 2025

Via Chartmill

Genmab Announces Topline Results for Epcoritamab (DuoBody® CD3xCD20) from Phase 3 EPCORE® DLBCL-1 Trial in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)

January 16, 2026

From Genmab A/S

Via Business Wire

Why Are Investors Paying Attention To Genmab Stock? ↗

January 07, 2026

Via Benzinga

Genmab Partners with Anthropic to Accelerate Research and Development Through Agentic Artificial Intelligence

January 07, 2026

From Genmab A/S

Via Business Wire

Genmab Stock Slips After Discontinuing Further Development Of Cancer Drug Developed With BioNTech ↗

December 29, 2025

Via Stocktwits

Biopharma’s Year-End Rollercoaster: Mereo Plummets 90% as BioMarin Seals $4.8 Billion Amicus Deal

December 29, 2025

Via MarketMinute

Genmab Portfolio Prioritization Update

December 29, 2025

From Genmab A/S

Via Business Wire

Genmab Announces Completion of Tender Offer for Outstanding Common Shares of Merus N.V. and Commencement of Subsequent Offering Period

December 12, 2025

From Genmab A/S

Via Business Wire

Genmab Announces New Data from Phase 1b/2 EPCORE® CLL-1 Highlighting Potential of Epcoritamab as Monotherapy and in Combination for Patients with Richter Transformation (RT)

December 08, 2025

From Genmab A/S

Via Business Wire

Genmab Presents Pivotal Phase 3 Data from EPCORE® FL-1 Trial Demonstrating Clinical Benefit of EPKINLY® (epcoritamab-bysp) in Combination with Rituximab and Lenalidomide (R2) in Patients with Relapsed or Refractory Follicular Lymphoma

December 07, 2025

From Genmab A/S

Via Business Wire

Genmab Announces Data From Multiple Clinical Trials Showing Treatment with Fixed-Duration Epcoritamab Led to Remissions in First-Line Diffuse Large B-Cell Lymphoma (DLBCL) and Follicular Lymphoma (FL)

December 06, 2025

From Genmab A/S

Via Business Wire

Genmab (GMAB) Q3 2025 Earnings Call Transcript ↗

November 27, 2025

Via The Motley Fool

Major Victory For Genmab As Epkinly Receives FDA Approval For Type Of Pretreated Blood Cancer ↗

November 18, 2025

Via Benzinga

Genmab Announces EPKINLY® (epcoritamab-bysp) in Combination with Rituximab and Lenalidomide Approved by the U.S. Food and Drug Administration for the Treatment of Relapsed or Refractory Follicular Lymphoma

November 18, 2025

From Genmab A/S

Via Business Wire

Halozyme Stock Surging On Recent Earnings Beat; Record High Ahead? ↗

November 12, 2025

Via Investor's Business Daily

Zscaler To Rally More Than 9%? Here Are 10 Top Analyst Forecasts For Monday ↗

November 10, 2025

Via Benzinga

Genmab to Showcase Latest Blood Cancer Treatment Advancements at 2025 American Society of Hematology (ASH) Annual Meeting

November 03, 2025

From Genmab A/S

Via Business Wire

Why Is Genmab Stock Trading Lower On Monday? ↗

October 20, 2025

Via Benzinga

Olema Pharmaceuticals, Exelixis, Genmab And Other Big Stocks Moving Lower In Monday's Pre-Market Session ↗

October 20, 2025

Via Benzinga

Frequently Asked Questions

Is Genmab A/S - American Depositary Shares publicly traded?

Yes, Genmab A/S - American Depositary Shares is publicly traded.

What exchange does Genmab A/S - American Depositary Shares trade on?

Genmab A/S - American Depositary Shares trades on the Nasdaq Stock Market

What is the ticker symbol for Genmab A/S - American Depositary Shares?

The ticker symbol for Genmab A/S - American Depositary Shares is GMAB on the Nasdaq Stock Market

What is the current price of Genmab A/S - American Depositary Shares?

The current price of Genmab A/S - American Depositary Shares is 28.89

When was Genmab A/S - American Depositary Shares last traded?

The last trade of Genmab A/S - American Depositary Shares was at 02/19/26 01:58 PM ET

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.